Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
- 1 June 2004
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (12) , S68-S72
- https://doi.org/10.1016/j.jacc.2004.02.031
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial HypertensionHeart Failure Reviews, 2003
- A 4-year update on the safety of sildenafil citrate (Viagra®)Urology, 2002
- Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Sildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary HypertensionAnesthesiology, 2000
- Molecular Basis of Cell-specific Endothelial Nitric-oxide Synthase Expression in Airway EpitheliumPublished by Elsevier ,2000
- Cell Type-Specific mRNA Quantitation in Non-Neoplastic Tissues after Laser-Assisted Cell PickingPathobiology, 2000
- Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxideJournal of Applied Physiology, 1999
- Use of Sildenafil (Viagra) in Patients With Cardiovascular DiseaseCirculation, 1999
- Cyclic nucleotide phosphodiesterases: functional implications of multiple isoformsPhysiological Reviews, 1995
- Ca/CaM-Stimulated and cGMP-Specific Phosphodiesterases in Vascular and Non-Vascular TissuesPublished by Springer Nature ,1991